$PEN

Penumbra Inc (PEN) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 pen-63026xexhibit991.htm EX-99.1 Document Exhibit 99.1 Penumbra, Inc. Reports Second Quarter 2026 Financial Results ALAMEDA, Calif., July 30, 2026 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN), the world’s leading thrombectomy company, today reported financial results for

Penumbra (NYSE: PEN) reported THUNDER IDE study results for its THUNDERBOLT computer-assisted vacuum thrombectomy system in emergent large vessel occlusion stroke. In 216 patients, 87.5% achieved mTICI 2b-3 reperfusion, with median time-to-revascularization of 20 minutes and 2.8% device/procedure-related serious adverse events. FDA clearance and CE Mark were noted.

Peninsula Energy Limited (ASX:PEN) shares fell about 26.03% intraday on 22 July 2026, according to a market snapshot. The company operates the Lance ISR uranium project in Wyoming and reaffirmed 2026 guidance of 400,000 to 500,000 lb U3O8 and 2027 guidance of 500,000 to 600,000 lb. In May 2026 it secured about US$56m funding. No specific disclosure was identified for the exact move.

Penumbra said the FDA cleared its Thunderbolt computer-assisted vacuum thrombectomy device for acute ischemic stroke, aimed at distal occlusions. Thunderbolt uses modulated aspiration with standard aspiration to help remove clots more completely. IDE study results will be presented in July, and Penumbra also reported a CE Mark and starting the Forward study.

Pennant International Group plc (AIM: PEN) said it has made its first sale of Auxilium–GenS via its Siemens partnership to a North American digital engineering customer supporting defence, national security and space missions. The sale follows a July 2025 agreement under which Siemens Digital Industries Software is licensed to distribute Auxilium–GenS through its Teamcenter platform.

Penumbra Inc (PEN) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. pen-20260618 0001321732 FALSE 0001321732 2022-06-01 2022-06-01 __________________________________________________________________________________________________________________________ UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ______________________

Vanguard Capital Management has reported a beneficial ownership of 1,990,629 shares in Penumbra Inc. (NYSE: PEN), which represents a 5.07% stake. This information is disclosed in a Schedule 13G SEC filing, indicating Vanguard's passive investment intentions. The filing details Vanguard's sole dispositive power over all 1.99 million shares and sole voting power over 296,141 shares, signed by Ashley Grim.

Penumbra has announced its 2026 annual stockholder meeting for June 18, 2026, where shareholders will vote on director elections, auditor ratification, and executive compensation. A separate special meeting will address the proposed $14.5 billion acquisition by Boston Scientific Corporation, valuing Penumbra shares at $374 each, with consideration split between cash and Boston Scientific stock. The proxy statement details the financial terms of the merger and outlines the company's executive compensation philosophy, which emphasizes base salary and long-term equity awards.

Penumbra Inc. (PEN) filed an ARS form with the SEC on April 29, 2026. This filing is available as a PDF document and has a low impact and neutral sentiment. The article also provides an overview of Penumbra, including its market capitalization, recent news, and other SEC filings.

Bamco Inc. NY significantly reduced its stake in Penumbra, Inc. by 22.9% in the third quarter, now holding 13,500 shares valued at $3.42 million. This comes after company insiders also sold a substantial number of shares, including CFO Maggie Yuen. Despite these sales, analysts maintain a consensus "Hold" rating on Penumbra, with an average price target of $361.69, even though the company recently missed EPS estimates but saw a 22.2% increase in revenue.